Theranostics 2020; 10(6):2453-2462. doi:10.7150/thno.42981

Research Paper

Tumor pH-responsive metastable-phase manganese sulfide nanotheranostics for traceable hydrogen sulfide gas therapy primed chemodynamic therapy

Ting He1,2‡, Xialing Qin1‡, Chao Jiang1, Dawei Jiang1, Shan Lei1, Jing Lin1, Wei-Guo Zhu3, Junle Qu2, Peng Huang1✉

1. Marshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen 518060, China.
2. Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China.
3. Guangdong Key Laboratory of Genome Instability and Human Disease Prevention, Carson International Cancer Center, Department of Biochemistry and Molecular Biology, Shenzhen.
University School of Medicine, Shenzhen 518055, China.
‡ These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
He T, Qin X, Jiang C, Jiang D, Lei S, Lin J, Zhu WG, Qu J, Huang P. Tumor pH-responsive metastable-phase manganese sulfide nanotheranostics for traceable hydrogen sulfide gas therapy primed chemodynamic therapy. Theranostics 2020; 10(6):2453-2462. doi:10.7150/thno.42981. Available from http://www.thno.org/v10p2453.htm

File import instruction

Abstract

Manganese-based nanomaterials have piqued great interest in cancer nanotheranostics, owing to their excellent physicochemical properties. Here we report a facile wet-chemical synthesis of size-controllable, biodegradable, and metastable γ-phase manganese sulfide nanotheranostics, which is employed for tumor pH-responsive traceable gas therapy primed chemodynamic therapy (CDT), using bovine serum albumin (BSA) as a biological template (The final product was denoted as MnS@BSA). The as-prepared MnS@BSA can be degraded in response to the mildly acidic tumor microenvironment, releasing hydrogen sulfide (H2S) for gas therapy and manganese ions for magnetic resonance imaging (MRI) and CDT. In vitro experiments validated the pH-responsiveness of MnS@BSA at pH 6.8 and both H2S gas and •OH radicals were detected during its degradation. In vivo experiments showed efficiently tumor turn-on T1-weighted MRI, significantly suppressed tumor growth and greatly prolonged survival of tumor-bearing mice following intravenous administration of MnS@BSA. Our findings indicated that MnS@BSA nanotheranostics hold great potential for traceable H2S gas therapy primed CDT of cancer.

Keywords: manganese sulfide, hydrogen sulfide, gas therapy, chemodynamic therapy, nanotheranostics.